Sugi Predict

Sugi Predict / Compounds / SCHEMBL707997

SCHEMBL707997

SCHEMBL707997

CS(=O)(=O)c1cc(Br)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ WDR5 P61964 5/20 0.42
▸ CCR2 P41597 3/20 0.41
▸ NMT1 P30419 1/20 0.39
▸ KAT6A Q92794 1/20 0.39
▸ ACLY P53396 1/20 0.38
▸ AKR1B1 P15121 1/20 0.38
▸ APLNR P35414 2/20 0.37
▸ DGAT1 O75907 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NR1H2 P55055 1/20 0.36
▸ NR1H3 Q13133 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430705 0.83 NMT1 (0.49) CCR2NMT1AKR1B1APLNRDGAT1
SCHEMBL1581645 0.83 NMT1 (0.49) CCR2NMT1AKR1B1APLNRDGAT1
SCHEMBL3112984 0.80 CCR2 (0.44) WDR5CCR2TSHRGLASMN1; SMN2
SCHEMBL15352355 0.80 APLNR (0.42) WDR5NMT1KAT6AACLYAKR1B1
SCHEMBL1790226 0.79 FLT1 (0.39) WDR5NMT1KAT6AACLYAKR1B1
SCHEMBL1348786 0.79 CA2 (0.45) ACLYAKR1B1APLNRDGAT1
SCHEMBL28038557 0.79 ACLY (0.41) WDR5NMT1KAT6AACLYAKR1B1
SCHEMBL31429890 0.79 MAPT (0.45) WDR5NMT1KAT6AACLYTSHR
SCHEMBL31429893 0.79 TSHR (0.41) NMT1KAT6AACLYTSHRSMN1; SMN2
SCHEMBL5097716 0.78 CCR2 (0.49) CCR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4567035-A1 NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Nextgen Bioscience Co., Ltd. (KR) 2025-06-11 — — EP disclosed
CN-119654324-A Novel compounds as hypoxia inducible factor 1 (HIF-1) inhibitors or Vascular Endothelial Growth Factor (VEGF) inhibitors and pharmaceutical compositions comprising the same 株式会社次代生物科学 2025-03-18 — — CN disclosed
US-20240360131-A1 BIARYL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-10-31 — — US disclosed
US-12065437-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-20 — — US disclosed
US-20210277001-A1 BIARYL KINASE INHIBITORS Cosmic Pet LLC 2021-09-09 — — US disclosed
US-10981910-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2021-04-20 — — US disclosed
CN-112142655-A Biaryl kinase inhibitors 百时美施贵宝公司 2020-12-29 — — CN disclosed
CN-108368084-B Biaryl kinase inhibitors 百时美施贵宝公司 2020-10-16 — — CN disclosed
US-20200317671-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-10-08 — — US disclosed
US-10723734-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-07-28 — — US disclosed
EP-2459558-A2 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 — — EP disclosed
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 — — US disclosed
WO-2011014795-A2 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 — — WO disclosed
WO-2011002814-A2 BIARYL OXYACETIC ACID COMPOUNDS LIGAND PHARMACEUTICALS INC. (US) 2011-01-06 — — WO disclosed
WO-2011002814-A2 BIARYL OXYACETIC ACID COMPOUNDS LIGAND PHARMACEUTICALS INC. (US) 2011-01-06 — — WO disclosed
WO-2010102154-A2 BIARYL OXYACETIC ACID COMPOUNDS LIGAND PHARMACEUTICALS INCORPORATED (US) 2010-09-10 — — WO disclosed
WO-2010102154-A2 BIARYL OXYACETIC ACID COMPOUNDS LIGAND PHARMACEUTICALS INCORPORATED (US) 2010-09-10 — — WO disclosed
WO-2010100144-A1 FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE MERCK SERONO S.A. (CH) 2010-09-10 — — WO disclosed
US-20100137250-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-06-03 — — US disclosed
WO-2009133127-A1 FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS MERCK SERONO S.A. (CH) 2009-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981910-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS WDR5 892/4885CCR2 3851/4885NMT1 3456/4885
US-20100137250-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 WDR5 4546/4885CCR2 1099/4885NMT1 606/4885
US-20210277001-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS WDR5 892/4885CCR2 3851/4885NMT1 3456/4885
US-20200317671-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS WDR5 892/4885CCR2 3851/4885NMT1 3456/4885
US-12065437-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS WDR5 892/4885CCR2 3851/4885NMT1 3456/4885
US-10723734-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS WDR5 892/4885CCR2 3851/4885NMT1 3456/4885
US-20240360131-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS WDR5 892/4885CCR2 3851/4885NMT1 3456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.